• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核转录因子 NF-κB 信号通路相关激酶激活剂 1(TAK1)及其上游调节因子核基质蛋白(Nuclear Met)在肿瘤的发生、发展中发挥着重要作用。研究发现,Nuclear Met 通过与 TAK1 相互作用,促进其激活,进而上调 NF-κB 信号通路的活性,从而促进肝癌的发生和转移。

Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.

机构信息

Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

School of Biological Sciences, The University of Hong Kong, Hong Kong, China.

出版信息

Cancer Lett. 2017 Dec 28;411:150-161. doi: 10.1016/j.canlet.2017.09.047. Epub 2017 Oct 6.

DOI:10.1016/j.canlet.2017.09.047
PMID:28989054
Abstract

Presence of Met receptor tyrosine kinase in the nucleus of cells has been reported. However, the functions of Met which expresses in the nucleus (nMet) remain elusive. In this study, we found that nMet was increased in 89% of HCC tumorous tissues when compared with the corresponding non-tumorous liver tissues. nMet expression increased progressively along HCC development and significantly correlated with cirrhosis, poorer cellular differentiation, venous invasion, late stage HCC and poorer overall survival. Western blot analysis revealed that nMet is a 48-kDa protein comprising the carboxyl terminal of Met receptor. Induced expression of nMet promoted HCC cell growth, migration and invasiveness in vitro and tumorigenesis and pulmonary metastasis in vivo. Luciferase assay showed that nMet activated NF-κB pathway. Indeed, p-IKKα/β and nuclear p-p65 were higher in nMet stable cells than in the control cells. Perturbation of TAK1/NF-κB axis abrogated the aggressiveness of HCC cells, both in vitro and in vivo. In conclusion, nMet was overexpressed and as a potential prognostic biomarker of HCC. Functionally, nMet accelerated HCC tumorigenesis and metastasis via the activation of TAK1/NF-κB pathway.

摘要

已经有报道称,Met 受体酪氨酸激酶存在于细胞核中。然而,表达在细胞核中的 Met(nMet)的功能仍然难以捉摸。在这项研究中,我们发现与相应的非肿瘤性肝组织相比,nMet 在 89%的 HCC 肿瘤组织中增加。nMet 的表达随着 HCC 的发展而逐渐增加,并且与肝硬化、较差的细胞分化、静脉侵犯、晚期 HCC 和较差的总体生存率显著相关。Western blot 分析显示,nMet 是一种 48kDa 的蛋白质,包含 Met 受体的羧基末端。nMet 的诱导表达促进了 HCC 细胞在体外的生长、迁移和侵袭,以及体内的肿瘤发生和肺转移。荧光素酶测定显示,nMet 激活了 NF-κB 通路。事实上,nMet 稳定细胞中的 p-IKKα/β 和核内 p-p65 高于对照细胞。干扰 TAK1/NF-κB 轴可消除 HCC 细胞的侵袭性,无论是在体外还是体内。总之,nMet 在 HCC 中过表达,并作为 HCC 的一个潜在预后生物标志物。在功能上,nMet 通过激活 TAK1/NF-κB 通路加速了 HCC 的肿瘤发生和转移。

相似文献

1
Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.核转录因子 NF-κB 信号通路相关激酶激活剂 1(TAK1)及其上游调节因子核基质蛋白(Nuclear Met)在肿瘤的发生、发展中发挥着重要作用。研究发现,Nuclear Met 通过与 TAK1 相互作用,促进其激活,进而上调 NF-κB 信号通路的活性,从而促进肝癌的发生和转移。
Cancer Lett. 2017 Dec 28;411:150-161. doi: 10.1016/j.canlet.2017.09.047. Epub 2017 Oct 6.
2
Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.肿瘤坏死因子α诱导蛋白 1 通过选择性地下调 CSNK2B 作为一种新型肿瘤抑制因子,阻断肝癌中核因子-κB 的激活。
EBioMedicine. 2020 Jan;51:102603. doi: 10.1016/j.ebiom.2019.102603. Epub 2020 Jan 3.
3
EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.EYA4 通过抑制 NF-κB 依赖的 RAP1 反式激活来抑制肝癌的生长和侵袭。
Cancer Commun (Lond). 2018 Apr 3;38(1):9. doi: 10.1186/s40880-018-0276-1.
4
MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.微小RNA-26b通过靶向转化生长因子β激活激酶1(TAK1)和TGFβ激活激酶1结合蛋白3(TAB3)抑制核因子κB(NF-κB)信号传导并增强肝癌细胞的化学敏感性。
Mol Cancer. 2014 Feb 24;13:35. doi: 10.1186/1476-4598-13-35.
5
Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.慢病毒介导的抗骨桥蛋白微小RNA抑制人肝细胞癌的肿瘤生长和转移。
Hepatology. 2008 Dec;48(6):1834-42. doi: 10.1002/hep.22531.
6
Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.ATP 酶抑制因子 1 与 NF-κB 的相互激活促进肝癌血管生成和转移。
Hepatology. 2014 Nov;60(5):1659-73. doi: 10.1002/hep.27312. Epub 2014 Oct 2.
7
MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.MAP4K4促进肝细胞癌的上皮-间质转化和转移。
Tumour Biol. 2016 Aug;37(8):11457-67. doi: 10.1007/s13277-016-5022-1. Epub 2016 Mar 24.
8
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.CYLD 的下调作为 NF-κB 激活的触发因素和肝癌细胞凋亡抵抗的机制。
Int J Oncol. 2011 Jan;38(1):121-31.
9
SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.SIX4 通过上调 YAP1 和 c-MET 促进肝癌转移。
Oncogene. 2020 Dec;39(50):7279-7295. doi: 10.1038/s41388-020-01500-y. Epub 2020 Oct 12.
10
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.转化生长因子β1(TGF-β1)通过TAK1/IKK激酶途径对核因子κB(NF-κB)的瞬时激活抑制AP-1/SMAD信号传导和细胞凋亡:对肝肿瘤形成的影响
Oncogene. 2003 Jan 23;22(3):412-25. doi: 10.1038/sj.onc.1206132.

引用本文的文献

1
Subcellular Organelle Targeting as a Novel Approach to Combat Tumor Metastasis.亚细胞器靶向:一种对抗肿瘤转移的新方法
Pharmaceutics. 2025 Feb 5;17(2):198. doi: 10.3390/pharmaceutics17020198.
2
Liver cancer cells with nuclear MET overexpression release translation regulatory protein-enriched extracellular vesicles exhibit metastasis promoting activity.细胞核MET过表达的肝癌细胞释放富含翻译调节蛋白的细胞外囊泡,具有促进转移的活性。
J Extracell Biol. 2022 May 8;1(5):e39. doi: 10.1002/jex2.39. eCollection 2022 May.
3
p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
p53调节NF1相关恶性外周神经鞘膜瘤中的激酶抑制剂抗性和谱系可塑性。
Oncogene. 2024 May;43(19):1411-1430. doi: 10.1038/s41388-024-03000-9. Epub 2024 Mar 13.
4
Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis.乳酸脱氢酶 A 通过 TAK1/NF-κB 轴促进鼻咽癌的进展。
Mol Biol Rep. 2024 Jan 18;51(1):152. doi: 10.1007/s11033-023-09130-9.
5
Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.基于胰腺癌活检的微流控类器官培养用于化疗和免疫治疗的个体化检测。
Adv Sci (Weinh). 2024 Feb;11(5):e2303088. doi: 10.1002/advs.202303088. Epub 2023 Nov 29.
6
Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.基于 PANoptosis 的预后签名用于预测肝细胞癌免疫治疗和化疗疗效的鉴定。
Genet Res (Camb). 2023 Jun 5;2023:6879022. doi: 10.1155/2023/6879022. eCollection 2023.
7
GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.GRAMD4 通过募集 E3 连接酶 ITCH 来靶向降解 TAK1 抑制肝癌转移。
Clin Transl Med. 2021 Nov;11(11):e635. doi: 10.1002/ctm2.635.
8
TAK1: A Molecular Link Between Liver Inflammation, Fibrosis, Steatosis, and Carcinogenesis.转化生长因子β激活激酶1(TAK1):肝脏炎症、纤维化、脂肪变性与致癌作用之间的分子联系
Front Cell Dev Biol. 2021 Oct 14;9:734749. doi: 10.3389/fcell.2021.734749. eCollection 2021.
9
Intermediate between Idiopathic Hypereosinophilia and Chronic Eosinophilic Leukemia: A Report of Two Hypereosinophilic Cases with Possible Novel Molecular Mutations.特发性嗜酸性粒细胞增多症与慢性嗜酸性粒细胞白血病之间的中间状态:两例可能存在新型分子突变的嗜酸性粒细胞增多症病例报告。
Case Rep Hematol. 2021 Aug 31;2021:1142124. doi: 10.1155/2021/1142124. eCollection 2021.
10
LncRNA TUG1 exhibits pro-fibrosis activity in hypertrophic scar through TAK1/YAP/TAZ pathway via miR-27b-3p.长链非编码 RNA TUG1 通过 miR-27b-3p 调控 TAK1/YAP/TAZ 通路促进增生性瘢痕成纤维细胞的纤维化。
Mol Cell Biochem. 2021 Aug;476(8):3009-3020. doi: 10.1007/s11010-021-04142-0. Epub 2021 Mar 31.